STADA Arzneimittel AG

Press release: STADA and Xbrane launch ranibizumab to support patient access in Europe

STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...

Press release: STADA sustains strong momentum with double-digit sales and profit growth in 2022

Press release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...

Press release: Adalvo and STADA extend their strategic partnership

Adalvo and STADA extend their strategic partnership - Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes - Adalvo CEO Anil Okay: “These new agreements demonstrate the significance of the strategic partnership we have built with STADA, in the last couple of years. We take ...

Press release: STADA appoints Boris Döbler as Chief Financial Officer

3

Press release: STADA ranks among top 10% of pharma firms on sustainability

Press release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe

Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...

3

Press release: STADA starts work on >EUR50m facility to strengthen European medicines supply

Press release: Stéphane Jacqmin joins STADA from Sanofi and becomes Head of Emerging Markets

Press release: STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...

Press release: STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease

STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease - Germany is STADA’s lead launch market for EU’s first authorized treatment for a rare kidney disease immunoglobulin A ...

Press release: Strong in-market performance leads STADA to double-digit growth

Strong in-market performance leads STADA to double-digit growth - Continued strong organic market-share gains across key European markets, supported by several launches - Adjusted Group sales advance by 15% while adjusted EBITDA improve by 23% in first half of 2022 - STADA CEO Peter Goldschmidt: “In ...

Press release: STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy

STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy - The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a ...

STADA Health Report 2022: Europe experiencing worsening health conditions

STADA Health Report 2022: Europe experiencing worsening health conditions - Self-assessed burnout rates at all-time high; stress levels have increased; more than one in three are struggling with sleep; appreciation for healthcare systems decreases after Covid high - STADA Health Report 2022: ...

Press release: STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab

STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab - Offers a comprehensive range of presentations to the EU adalimumab biosimilars market - Adalimumab marks the first molecule ...

Press release: STADA set to expand Specialty portfolio after positive CHMP opinion on Kinpeygo orphan medicine for IgA nephropathy

STADA set to expand Specialty portfolio after positive CHMP opinion on KinpeygoTM orphan medicine for IgA nephropathy - CHMP within the European Medicines Agency issues positive opinion on KinpeygoTM, a novel oral formulation of budesonide, for ...